- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in AdultsTu, Sanfang; Zhou, Lijuan; Huang, Rui; Zhou, Xuan; Yang, Jilong; Li, Meifang; Jin, Bo; Wang, Langqi; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaWang, Langqi; Yang, Jilong; Jin, Bo; Wang, Bo; Zhou, Lijuan; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Tu, Sanfang; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System InvolvementHe, Bailin; Zhou, Hongsheng; Lin, Ren; Wang, Zhixiang; Xu, Na; Wang, Qiang; Sun, Jing; Liu, Xiaoli; Li, Peng; Liu, Qifa65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
13阅读
